IMPACTfolio LLC Reduces Holdings in Zoetis Inc. (NYSE:ZTS)

IMPACTfolio LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 2,572 shares of the company’s stock after selling 118 shares during the quarter. Zoetis makes up about 0.2% of IMPACTfolio LLC’s portfolio, making the stock its 25th biggest holding. IMPACTfolio LLC’s holdings in Zoetis were worth $419,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. JPMorgan Chase & Co. boosted its stake in Zoetis by 10.6% during the third quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock worth $569,834,000 after buying an additional 279,092 shares during the last quarter. Peapack Gladstone Financial Corp boosted its position in shares of Zoetis by 1.8% during the 3rd quarter. Peapack Gladstone Financial Corp now owns 77,004 shares of the company’s stock valued at $15,045,000 after acquiring an additional 1,393 shares during the last quarter. Tidal Investments LLC grew its holdings in shares of Zoetis by 3.4% in the third quarter. Tidal Investments LLC now owns 15,210 shares of the company’s stock valued at $2,972,000 after purchasing an additional 500 shares during the period. Destination Wealth Management increased its position in Zoetis by 0.8% during the third quarter. Destination Wealth Management now owns 123,844 shares of the company’s stock worth $24,197,000 after purchasing an additional 1,027 shares during the last quarter. Finally, Wilmington Savings Fund Society FSB raised its stake in Zoetis by 801.0% during the third quarter. Wilmington Savings Fund Society FSB now owns 18,606 shares of the company’s stock worth $3,635,000 after purchasing an additional 16,541 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.1 %

Shares of NYSE ZTS traded down $0.18 during mid-day trading on Thursday, hitting $162.75. The company had a trading volume of 1,239,996 shares, compared to its average volume of 2,532,374. Zoetis Inc. has a 1-year low of $144.80 and a 1-year high of $200.53. The company has a market capitalization of $73.43 billion, a PE ratio of 30.59, a price-to-earnings-growth ratio of 2.91 and a beta of 0.89. The company has a debt-to-equity ratio of 1.26, a current ratio of 3.69 and a quick ratio of 2.27. The business’s 50-day simple moving average is $174.12 and its 200 day simple moving average is $180.51.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Monday, November 4th. The company reported $1.58 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.12. The business had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a return on equity of 51.98% and a net margin of 26.55%. The business’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same period in the previous year, the company posted $1.36 earnings per share. On average, analysts predict that Zoetis Inc. will post 5.9 earnings per share for the current year.

Zoetis Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.23%. The ex-dividend date is Tuesday, January 21st. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. Zoetis’s dividend payout ratio (DPR) is 37.59%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. JPMorgan Chase & Co. raised their price target on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. UBS Group assumed coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 target price for the company. Leerink Partners began coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 price target for the company. Stifel Nicolaus boosted their price objective on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Finally, Leerink Partnrs raised shares of Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $215.22.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.